Researchers reported progress in nanovaccine platforms designed to stimulate antitumor immunity against hepatocellular carcinoma (HCC). The study details nanoparticle formulations that deliver tumor antigens and adjuvants to antigen‑presenting cells, enhancing T‑cell responses in preclinical models. Authors highlight improved immunogenicity and tumor control versus conventional vaccine strategies and discuss combinability with checkpoint inhibitors. The paper signals a maturing area of cancer vaccinology focused on delivery engineering and immune orchestration for liver malignancies.